Saturday 17 October 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.87
0.25
−6.07%
Follow TMCI
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | 1 | 3 | 4 | 2 |
Altman Z-Score |
— | — | — | 12.23 | 7.94 | 4.14 | 2.25 | (0.11) |
P/S ratio |
— | 14.91 | 14.91 | 9.56 | 8.73 | 4.08 | 2.21 | 0.73 |
Altman Z″-Score (non-manufacturers) |
— | — | 3.10 | 5.87 | 1.69 | 2.15 | 0.38 | (1.79) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | (1.89) | (2.44) | (2.05) | (2.81) | (3.51) |
P/Operating CF |
— | (2,166.88) | (2,166.88) | (240.53) | (230.99) | 1,436.66 | (109.84) | (19.31) |
P/B ratio |
— | 0.00 | 0.00 | 9.70 | 20.45 | 5.54 | 4.09 | 1.77 |
Price to Tangible BV |
— | 0.00 | 0.00 | 9.70 | 20.45 | 6.58 | 5.02 | 2.30 |
EV/Sales |
— | 15.14 | 15.14 | 8.77 | 8.54 | 3.72 | 2.11 | 0.77 |
EV/EBITDA |
— | 524.01 | 524.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (242.64) | (242.64) | (48.16) | (39.51) | (20.13) | (11.88) | (10.27) |
EV/FCF |
— | (211.71) | (211.71) | (41.61) | (26.62) | (15.12) | (9.06) | (5.56) |
Quick Ratio |
— | 3.08 | 2.81 | 6.83 | 3.65 | 3.58 | 3.34 | 2.95 |
Current Ratio |
— | 3.90 | 3.53 | 7.58 | 4.41 | 4.40 | 4.62 | 4.31 |
Net Debt/EBITDA |
— | (2.73) | 5.75 | 4.88 | 0.88 | 1.49 | 0.46 | (0.17) |
Debt/Assets |
0.00% | 0.00% | 74.68% | 20.98% | 33.15% | 21.04% | 24.55% | 29.17% |
Debt/Equity |
— | 0.00 | 40.23 | 0.32 | 0.87 | 0.38 | 0.47 | 0.64 |
Asset Turnover |
— | 0.00 | 2.74 | 1.03 | 0.95 | 0.91 | 0.89 | 1.04 |
Operating CF/Net income |
— | 1.56 | 1.04 | 0.83 | 0.72 | 0.70 | 0.67 | 0.27 |
Capex/Depreciation |
— | (1.29) | (0.75) | (3.14) | (6.59) | (2.70) | (1.53) | (1.25) |
Interest Coverage |
— | (4.20) | 0.31 | (4.07) | (7.92) | (9.95) | (10.60) | (10.18) |
| — | 82.21% | 72.20% | (48.30%) | (55.75%) | (49.91%) | (44.45%) | (58.94%) | |
| — | 0.00% | (20.61%) | (22.72%) | (28.56%) | (24.10%) | (23.77%) | (28.95%) | |
ROIC |
— | (31.19%) | 3.84% | (61.50%) | (68.08%) | (47.44%) | (38.45%) | (35.80%) |
Return on Tangible Assets |
— | (21.91%) | (14.26%) | (16.92%) | (36.13%) | (28.20%) | (36.57%) | (44.98%) |
Average Days of Receivables |
— | 96.41 | 92.17 | 71.78 | 75.13 | 74.25 | 71.14 | 72.34 |
Research and Development Expense of Revenue |
— | 12.86% | 10.19% | 10.81% | 9.58% | 8.25% | 9.83% | 9.54% |
Selling, General and Administrative Expense of Revenue |
— | 76.75% | 66.58% | 88.79% | 96.99% | 100.43% | 97.14% | 95.74% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.10 | 0.10 |
Share Based Compensation of Revenue |
— | 2.07% | 1.60% | 3.61% | 5.72% | 9.27% | 14.62% | 15.90% |
Graham Net Nets |
— | 0.00 | 0.00 | 0.10 | 0.03 | 0.11 | 0.12 | 0.19 |
Graham Number |
— | 0.00 | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (0.49%) | (0.49%) | (2.20%) | (3.44%) | (6.45%) | (12.10%) | (38.37%) |
Free Cash Flow Yield |
— | (0.48%) | (0.48%) | (2.20%) | (3.68%) | (6.02%) | (10.55%) | (19.02%) |
Revenue per Share |
— | 1.07 | 1.55 | 1.95 | 2.57 | 3.08 | 3.37 | 3.36 |
Operating CF per Share |
— | (0.21) | (0.12) | (0.36) | (0.55) | (0.57) | (0.60) | (0.25) |
Capex per Share |
— | (0.03) | (0.03) | (0.06) | (0.27) | (0.19) | (0.19) | (0.21) |
Free Cash Flow per Share |
— | (0.24) | (0.15) | (0.41) | (0.82) | (0.76) | (0.78) | (0.47) |
Cash per Share |
— | 0.33 | 0.49 | 2.19 | 1.47 | 2.02 | 1.22 | 0.76 |
Shareholders Equity per Share |
— | 0.00 | 0.02 | 1.92 | 1.10 | 2.27 | 1.82 | 1.38 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.02 | 1.92 | 1.10 | 2.27 | 1.82 | 1.38 |
Free Cash Flow |
— | (8.88) | (5.56) | (19.90) | (45.49) | (46.03) | (48.76) | (29.49) |
Working Capital |
— | 21.24 | 29.38 | 119.76 | 103.16 | 153.33 | 126.48 | 101.42 |
Capital Expenditures |
— | (1.21) | (1.07) | (2.70) | (14.84) | (11.46) | (11.59) | (13.52) |
Net Current Asset Value |
— | 28.57 | (0.05) | 90.22 | 34.91 | 84.39 | 57.20 | 28.81 |
EV/EBIT |
— | 1,505.34 | 1,505.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.03 | 0.02 | 0.03 | 0.10 | 0.06 | 0.06 | 0.06 |
Price to Operating Income |
— | 1,482.26 | 1,482.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.82 | 1.73 | 0.30 | 0.15 | 0.19 | 0.29 | 0.36 |
Cash ROIC |
— | (28.33%) | (11.11%) | (8.71%) | (23.39%) | (14.65%) | (20.16%) | (15.42%) |
Accounts Receivable Turnover |
— | 3.17 | 4.61 | 5.71 | 5.94 | 5.56 | 5.31 | 5.13 |
Accounts Payable Turnover |
— | 4.78 | 7.80 | 5.34 | 4.01 | 3.43 | 3.68 | 4.98 |
Inventory Turnover |
— | 1.14 | 1.86 | 1.84 | 1.71 | 1.45 | 1.20 | 1.14 |
Average Days of Payables |
— | 44.53 | 66.30 | 87.66 | 123.92 | 122.79 | 93.46 | 57.18 |
Days of Inventory on Hand |
— | 266.04 | 228.89 | 228.25 | 276.34 | 303.41 | 348.67 | 306.29 |
Average Receivables |
— | 12.45 | 12.45 | 16.53 | 23.88 | 33.63 | 39.43 | 41.48 |
Average Payables |
— | 1.60 | 1.60 | 3.16 | 6.36 | 10.25 | 11.18 | 8.62 |
Average Inventory |
— | 6.69 | 6.69 | 9.19 | 14.95 | 24.29 | 34.25 | 37.64 |
Average Assets |
— | 0.00 | 20.90 | 91.31 | 149.92 | 205.47 | 234.50 | 203.84 |
Average Common Equity |
— | (5.97) | (5.97) | 42.96 | 76.80 | 99.23 | 125.42 | 100.11 |
Columns are period end dates